What You Should Know:
– iCAD, Inc. (NASDAQ: ICAD), a provider of medical technology and innovative cancer-detection solutions, announced that its ProFound Breast Health Suite will be integrated into GE HealthCare’s new MyBreastAI Suite offering.
– This integration coincides with GE HealthCare’s and iCAD’s presence at the Radiological Society of North America (RSNA) annual meeting in Chicago as it unveils new research evaluating its ProFound AI in breast cancer risk detection and heart disease.
Advancing Breast Cancer Detection with AI
Breast cancer is the most commonly diagnosed cancer worldwide, and iCAD’s AI solutions are designed to address critical issues in breast imaging, including access, burnout, variability, equity, and cost. GE HealthCare’s MyBreastAI Suite, featuring iCAD’s three key AI-enabled solutions from ProFound Breast Health Suite, aims to streamline workflow and help clinicians in accelerating breast cancer detection and delivering more personalized and effective breast care.
iCAD’s AI-Powered Solutions
The MyBreastAI Suite will initially offer three AI applications from iCAD:
– ProFound Detection for Digital Breast Tomosynthesis (DBT): This deep-learning AI workflow solution rapidly evaluates 3D mammograms to detect malignant soft tissue densities and calcifications with unmatched accuracy. ProFound Detection provides Lesion Scores and Case Scores, aiding in clinical decision-making, workload prioritization, and potentially reducing burnout.
– SecondLook for 2D Mammography: Utilizes AI to identify potential cancers in 2D mammography, marking suspicious areas promptly and clearly.
– PowerLook Density Assessment: Automates breast density evaluation, providing an objective, reproducible measure that is crucial for personalized screening recommendations.
Clinical Benefits of iCAD’s AI Solutions
Clinical studies have demonstrated that the use of iCAD’s ProFound AI solutions can significantly improve reading sensitivity and specificity, as well as reduce reading times, thus enhancing clinical decision support and workflow efficiency for radiologists. Specifically, ProFound AI offers clinically proven time-saving benefits to radiologists, including a reduction of reading time by 52.7%, thereby halving the amount of time it takes radiologists to read 3D mammography datasets. Additionally, ProFound AI for DBT improved radiologist sensitivity by 8% and reduced unnecessary patient recall rates by 7.2%.
Availability and Collaboration
MyBreastAI Suite, featuring key iCAD AI-enhanced solutions, will be available first in the United States and distributed, installed, and supported by GE HealthCare as part of their Senographe Pristina mammography portfolio.
